KRT33A

Summary

KRT33A (keratin 33A, HGNC:6450) is a protein-coding gene on chromosome 17q21.2, encoding Keratin, type I cuticular Ha3-I (O76009). It is a selective cancer dependency (DepMap: 12.8% of cell lines).

This gene encodes a member of the keratin gene family. This gene is one of multiple type I hair keratin genes that are clustered in a region of chromosome 17q12-q21 and have the same direction of transcription. As a type I hair keratin, the encoded protein is an acidic protein which heterodimerizes with type II keratins to form hair and nails. There are two isoforms of this protein, encoded by two separate genes, keratin 33A and keratin 33B.

Source: NCBI Gene 3883 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 107 total
• Cancer dependency (DepMap): dependent in 12.8% of screened cell lines
• MANE Select transcript: NM_004138

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6450
Approved symbol	KRT33A
Name	keratin 33A
Location	17q21.2
Locus type	gene with protein product
Status	Approved
Aliases	Ha-3I, Krt1-3
Ensembl gene	ENSG00000006059
Ensembl biotype	protein_coding
OMIM	602761
Entrez	3883

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000007735

RefSeq mRNA: 1 — MANE Select: NM_004138 NM_004138

CCDS: CCDS11388

Canonical transcript exons

ENST00000007735 — 7 exons

Exon	Start	End
ENSE00002436555	41346844	41346969
ENSE00002454721	41350420	41350828
ENSE00002456065	41347061	41347222
ENSE00002459275	41346448	41346668
ENSE00002473036	41348483	41348639
ENSE00002483313	41349346	41349428
ENSE00002495543	41346092	41346236

Expression profiles

Bgee: expression breadth broad, 45 present calls, max score 84.73.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0239 / max 25.2491, expressed in 7 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
165887	0.0239	7

Top tissues by expression

114 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.73	gold quality
esophagus mucosa	UBERON:0002469	60.35	gold quality
left testis	UBERON:0004533	59.16	gold quality
right testis	UBERON:0004534	59.08	gold quality
testis	UBERON:0000473	58.58	gold quality
lower esophagus mucosa	UBERON:0035834	49.08	gold quality
esophagus	UBERON:0001043	43.55	gold quality
skin of abdomen	UBERON:0001416	42.57	gold quality
vagina	UBERON:0000996	41.61	gold quality
zone of skin	UBERON:0000014	41.00	gold quality
skin of leg	UBERON:0001511	40.07	gold quality
minor salivary gland	UBERON:0001830	39.14	gold quality
saliva-secreting gland	UBERON:0001044	38.25	gold quality
right lung	UBERON:0002167	37.79	gold quality
ectocervix	UBERON:0012249	37.35	gold quality
colonic epithelium	UBERON:0000397	37.20	gold quality
tonsil	UBERON:0002372	37.00	silver quality
skeletal muscle tissue	UBERON:0001134	36.54	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
cortical plate	UBERON:0005343	36.47	gold quality
granulocyte	CL:0000094	36.31	gold quality
bone marrow cell	CL:0002092	36.16	gold quality
ganglionic eminence	UBERON:0004023	35.49	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	35.05	silver quality
muscle tissue	UBERON:0002385	33.38	gold quality
uterine cervix	UBERON:0000002	32.18	gold quality
hindlimb stylopod muscle	UBERON:0004252	32.15	gold quality
hypothalamus	UBERON:0001898	31.97	gold quality
bone marrow	UBERON:0002371	31.74	gold quality
sural nerve	UBERON:0015488	30.93	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.59

Regulation

Is transcription factor: no

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 12.8% of screened cell lines.

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
mus_musculus	Krt33a	ENSMUSG00000035592
mus_musculus	Krt31	ENSMUSG00000048981
mus_musculus	Krt33b	ENSMUSG00000057723
rattus_norvegicus	Krt31	ENSRNOG00000030344
rattus_norvegicus	Krt33a	ENSRNOG00000062912
rattus_norvegicus	Krt33b	ENSRNOG00000068212

Paralogs (68): VIM (ENSG00000026025), KRT31 (ENSG00000094796), NEFM (ENSG00000104722), KRT23 (ENSG00000108244), KRT37 (ENSG00000108417), KRT32 (ENSG00000108759), KRT18 (ENSG00000111057), LMNB1 (ENSG00000113368), KRT36 (ENSG00000126337), KRT17 (ENSG00000128422), GFAP (ENSG00000131095), KRT34 (ENSG00000131737), KRT33B (ENSG00000131738), NES (ENSG00000132688), PRPH (ENSG00000135406), KRT85 (ENSG00000135443), KRT7 (ENSG00000135480), KRT71 (ENSG00000139648), INA (ENSG00000148798), LMNTD1 (ENSG00000152936), LMNA (ENSG00000160789), KRT84 (ENSG00000161849), KRT82 (ENSG00000161850), KRT80 (ENSG00000167767), KRT1 (ENSG00000167768), KRT24 (ENSG00000167916), KRT8 (ENSG00000170421), KRT78 (ENSG00000170423), KRT86 (ENSG00000170442), KRT75 (ENSG00000170454), KRT6C (ENSG00000170465), KRT4 (ENSG00000170477), KRT74 (ENSG00000170484), KRT72 (ENSG00000170486), KRT83 (ENSG00000170523), BFSP2 (ENSG00000170819), KRT19 (ENSG00000171345), KRT15 (ENSG00000171346), KRT38 (ENSG00000171360), KRT13 (ENSG00000171401)

Protein

Protein identifiers

Keratin, type I cuticular Ha3-I — O76009 (reviewed: O76009)

Alternative names: Hair keratin, type I Ha3-I, Keratin-33A

All UniProt accessions (1): O76009

UniProt curated annotations — full annotation on UniProt →

Tissue specificity. Expressed in the hair follicles.

Miscellaneous. There are two types of hair/microfibrillar keratin, I (acidic) and II (neutral to basic).

Similarity. Belongs to the intermediate filament family.

RefSeq proteins (1): NP_004129* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002957	Keratin_I	Family
IPR018039	IF_conserved	Conserved_site
IPR039008	IF_rod_dom	Domain

Pfam: PF00038

UniProt features (14 total): region of interest 7, sequence conflict 3, chain 1, domain 1, sequence variant 1, site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O76009-F1	80.46	0.61

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 305 (stutter)

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-6805567	Keratinization
R-HSA-6809371	Formation of the cornified envelope
R-HSA-1266738	Developmental Biology

MSigDB gene sets: 107 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_UP, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_EPITHELIUM_DEVELOPMENT, MORF_FLT1, CAR_TNFRSF25, GOBP_INTERMEDIATE_FILAMENT_BASED_PROCESS, GU_PDEF_TARGETS_DN, MORF_MSH3, GOBP_INTERMEDIATE_FILAMENT_ORGANIZATION, JAEGER_METASTASIS_DN, MORF_BRCA1, MORF_ATRX, MORF_ESR1, MORF_RAD51L3, MARTINEZ_RB1_TARGETS_DN

GO Biological Process (3): morphogenesis of an epithelium (GO:0002009), epithelial cell differentiation (GO:0030855), intermediate filament organization (GO:0045109)

GO Molecular Function (2): structural constituent of skin epidermis (GO:0030280), structural molecule activity (GO:0005198)

GO Cellular Component (5): obsolete extracellular space (GO:0005615), cytosol (GO:0005829), cytoskeleton (GO:0005856), keratin filament (GO:0045095), intermediate filament (GO:0005882)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Developmental Biology	1
Keratinization	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
epithelium development	2
tissue morphogenesis	1
cell differentiation	1
intermediate filament cytoskeleton organization	1
supramolecular fiber organization	1
structural molecule activity	1
molecular_function	1
cytoplasm	1
cellular anatomical structure	1
intracellular membraneless organelle	1
intermediate filament	1
intermediate filament cytoskeleton	1
polymeric cytoskeletal fiber	1

Protein interactions and networks

STRING

1234 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KRT33A	H3BSS0	H3BSS0	557
KRT33A	MT1A	P04731	550
KRT33A	KRT4	P19013	549
KRT33A	SPRR3	Q9UBC9	521
KRT33A	MT2A	P02795	497
KRT33A	DHFR2	Q86XF0	495
KRT33A	TGM3	Q08188	434
KRT33A	DHFR	P00374	423
KRT33A	MT4	P47944	414
KRT33A	KRT8	P05787	403
KRT33A	SCGB1A1	P11684	391
KRT33A	THRA	P10827	388
KRT33A	SPRR2A	P35326	385
KRT33A	NGFR	P08138	383
KRT33A	SPRR1A	P35321	370

IntAct

9 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
GRB2	CNOT1	psi-mi:“MI:0914”(association)	0.350
EPS15	KRT33A	psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
FHIP1A	ILVBL	psi-mi:“MI:2364”(proximity)	0.270
	KRT33A	psi-mi:“MI:0915”(physical association)	0.000
CDC20	KRT33A	psi-mi:“MI:0915”(physical association)	0.000
DNPEP	KRT33A	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (20): KRT33A (Affinity Capture-MS), KRT33A (Affinity Capture-MS), KRT33A (Affinity Capture-MS), KRT33A (Affinity Capture-MS), KRT33A (Affinity Capture-MS), KRT33A (Affinity Capture-MS), KRT33A (Affinity Capture-MS), KRT8 (Cross-Linking-MS (XL-MS)), KRT33A (Proximity Label-MS), KRT33A (Affinity Capture-MS), KRT33B (Co-fractionation), KRT85 (Co-fractionation), KRT33A (Co-fractionation), KRT34 (Co-fractionation), KRT83 (Co-fractionation)

ESM2 similar proteins: A4FUZ0, A5A6M5, A5A6P3, A6QNX5, A7YWK3, B0LKP1, B1AQ75, E1AB55, O43790, O76009, O76013, P02534, P15241, P19013, P25690, P25691, P78385, P78386, P97861, Q0P5J7, Q14525, Q14532, Q14533, Q148H4, Q148H5, Q148H7, Q148H8, Q14CN4, Q15323, Q3SY84, Q497I4, Q61765, Q61897, Q62168, Q6IG03, Q6IG04, Q6IME9, Q6IMF0, Q6NXH9, Q86Y46

Diamond homologs: A1KQY9, A1L317, A1L595, A5A6M0, A5A6M5, A5A6N2, A5A6P3, A6BLY7, A6QQQ9, A7YWM2, B0LKP1, B1AQ75, O57607, O57611, O76009, O76013, O77727, O93256, P02533, P02534, P02535, P02537, P05781, P05783, P05784, P06394, P08727, P08728, P08730, P08777, P08778, P08779, P08802, P13645, P13646, P19001, P19012, P25030, P25690, P35527

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

107 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	101
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

684 predictions. Top by Δscore:

Variant	Effect	Δscore
17:41346442:A:AC	donor_gain	1.0000
17:41346443:C:CC	donor_gain	1.0000
17:41346443:CTGA:C	donor_gain	1.0000
17:41346446:A:AC	donor_gain	1.0000
17:41346447:C:CC	donor_gain	1.0000
17:41346664:TCTCG:T	acceptor_gain	1.0000
17:41346665:CTCG:C	acceptor_gain	1.0000
17:41346665:CTCGC:C	acceptor_gain	1.0000
17:41346666:TCG:T	acceptor_gain	1.0000
17:41346666:TCGC:T	acceptor_gain	1.0000
17:41346667:CG:C	acceptor_gain	1.0000
17:41346667:CGC:C	acceptor_gain	1.0000
17:41346668:GC:G	acceptor_loss	1.0000
17:41346669:C:CC	acceptor_gain	1.0000
17:41346669:CT:C	acceptor_loss	1.0000
17:41346670:T:A	acceptor_loss	1.0000
17:41346671:G:C	acceptor_gain	1.0000
17:41346671:G:GC	acceptor_gain	1.0000
17:41346674:G:C	acceptor_gain	1.0000
17:41346674:G:GC	acceptor_gain	1.0000
17:41346840:ACACC:A	donor_loss	1.0000
17:41346841:CA:C	donor_loss	1.0000
17:41346965:TCGGT:T	acceptor_gain	1.0000
17:41346966:CGGT:C	acceptor_gain	1.0000
17:41346966:CGGTC:C	acceptor_gain	1.0000
17:41346967:GGT:G	acceptor_gain	1.0000
17:41346967:GGTC:G	acceptor_loss	1.0000
17:41346968:GT:G	acceptor_gain	1.0000
17:41346968:GTC:G	acceptor_loss	1.0000
17:41346970:C:CC	acceptor_gain	1.0000

AlphaMissense

2634 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:41350571:C:G	R66P	0.997
17:41350568:A:G	L67P	0.995
17:41346487:A:G	I353T	0.993
17:41346863:A:G	L286P	0.992
17:41349377:C:G	A134P	0.992
17:41350538:A:G	L77P	0.992
17:41350566:C:G	A68P	0.992
17:41346499:A:G	L349P	0.991
17:41346550:A:G	L332P	0.991
17:41350568:A:T	L67Q	0.991
17:41346469:A:G	L359P	0.990
17:41346487:A:C	I353S	0.990
17:41346571:A:G	L325P	0.990
17:41350556:A:G	L71P	0.990
17:41350580:A:G	L63P	0.990
17:41346520:A:G	L342P	0.989
17:41346541:T:G	Q335P	0.989
17:41346559:C:G	R329P	0.989
17:41350572:G:T	R66S	0.989
17:41350430:A:G	L113P	0.988
17:41346544:C:G	R334P	0.987
17:41346858:C:G	A288P	0.987
17:41350577:T:A	N64I	0.987
17:41346479:A:G	Y356H	0.986
17:41350517:A:G	L84P	0.986
17:41346475:C:G	R357P	0.985
17:41348565:A:G	L169P	0.985
17:41350576:G:C	N64K	0.984
17:41350576:G:T	N64K	0.984
17:41346479:A:C	Y356D	0.983

dbSNP variants (sampled 300 via entrez): RS1000170409 (17:41351200 A>C), RS1000276513 (17:41351413 G>A,C,T), RS1000679215 (17:41346761 G>A), RS1001909080 (17:41349643 C>T), RS1002762190 (17:41348035 A>G), RS1004189624 (17:41352560 A>G), RS1004286745 (17:41346595 A>C,G), RS1004339915 (17:41347652 A>G), RS1004772544 (17:41350847 G>A,C), RS1006643922 (17:41351455 C>A), RS1006759983 (17:41351906 A>G), RS1008077466 (17:41349299 C>T), RS1008174225 (17:41346552 G>A), RS1008297725 (17:41351567 C>T), RS1008744892 (17:41351882 G>A)

Disease associations

OMIM: gene MIM:602761 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006988_47	Blond vs. brown/black hair color	7.000000e-11

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0003924	hair color

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases expression, increases methylation	2
benzo(e)pyrene	decreases methylation	1
CGP 52608	affects binding, increases reaction	1
Resveratrol	affects cotreatment, decreases expression	1
Methapyrilene	decreases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Rotenone	decreases expression	1
Aflatoxin B1	decreases methylation	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer